![]() |
|
| Systematic (IUPAC) name | |
|---|---|
| (2-(2-methyl-1H-indol-3-yl)-1-methyl-ethyl)dimethylamine | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C 13H18N2 |
| Mol. mass | 202.30 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | ? |
2,N,N-trimethyltryptamine, 2,N,N-TMT, or 2-Me-DMT is a tryptamine derivative that is a hallucinogenic drug. It was invented by Alexander Shulgin and reported in his book TiHKAL (#34) [1]. It is claimed to show psychoactive effects at a dosage of 50-100mg orally, but these are relatively mild compared to other similar drugs, suggesting that while the 2-methyl group has blocked the binding of metabolic enzymes, it is also interfering with binding to the 5HT2A receptor target that mediates the hallucinogenic effects of these drugs.
|
|||||
|
|||||
|
|